These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
821 related articles for article (PubMed ID: 34445701)
1. CAR T-Cell Therapy in Hematological Malignancies. Haslauer T; Greil R; Zaborsky N; Geisberger R Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701 [TBL] [Abstract][Full Text] [Related]
2. Significant Advancements and Evolutions in Chimeric Antigen Receptor Design. Gaimari A; De Lucia A; Nicolini F; Mazzotti L; Maltoni R; Rughi G; Zurlo M; Marchesini M; Juan M; Parras D; Cerchione C; Martinelli G; Bravaccini S; Tettamanti S; Pasetto A; Pasini L; Magnoni C; Gazzola L; Borges de Souza P; Mazza M Int J Mol Sci; 2024 Nov; 25(22):. PubMed ID: 39596267 [TBL] [Abstract][Full Text] [Related]
3. CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review. Brudno JN; Maus MV; Hinrichs CS JAMA; 2024 Dec; 332(22):1924-1935. PubMed ID: 39495525 [TBL] [Abstract][Full Text] [Related]
4. A bibliometric and knowledge-map study on the treatment of hematological malignancies with CAR-T cells from 2012 to 2023. Huang Q; Li H; Zhang Y Hum Vaccin Immunother; 2024 Dec; 20(1):2371664. PubMed ID: 38961667 [TBL] [Abstract][Full Text] [Related]
5. Evolving strategies to overcome barriers in CAR-T cell therapy for acute myeloid leukemia. Colonne CK; Kimble EL; Turtle CJ Expert Rev Hematol; 2024 Nov; 17(11):797-818. PubMed ID: 39439295 [TBL] [Abstract][Full Text] [Related]
6. Applications and Opportunities for Immune Cell CAR Engineering in Comparative Oncology. Rotolo A; Atherton MJ Clin Cancer Res; 2024 Jun; 30(11):2359-2369. PubMed ID: 38573683 [TBL] [Abstract][Full Text] [Related]
7. [Construction of CD138-targeted chimeric antigen receptor- modified T cells and their effect in multiple myeloma therapy]. Guo CC; Lu Y; Tang KJ; Xing HY; Tian Z; Rao Q; Wang M; Xiong DS; Wang JX Zhonghua Xue Ye Xue Za Zhi; 2024 May; 45(5):436-444. PubMed ID: 38964917 [No Abstract] [Full Text] [Related]
9. Chimeric antigen receptor T-cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice. Grégoire C; Coutinho de Oliveira B; Caimi PF; Caers J; Melenhorst JJ Br J Haematol; 2024 Nov; 205(5):1699-1713. PubMed ID: 39262037 [TBL] [Abstract][Full Text] [Related]
10. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies. Niu Z; Wu J; Zhao Q; Zhang J; Zhang P; Yang Y Front Immunol; 2024; 15():1385571. PubMed ID: 38680498 [TBL] [Abstract][Full Text] [Related]
11. Fast on-rates of chimeric antigen receptors enhance the sensitivity to peptide MHC via antigen rebinding. Hiratsuka H; Akahori Y; Maeta S; Egashira Y; Shiku H J Biol Chem; 2024 Sep; 300(9):107651. PubMed ID: 39122001 [TBL] [Abstract][Full Text] [Related]
12. CD38 as a pan-hematologic target for chimeric antigen receptor T cells. Glisovic-Aplenc T; Diorio C; Chukinas JA; Veliz K; Shestova O; Shen F; Nunez-Cruz S; Vincent TL; Miao F; Milone MC; June CH; Teachey DT; Tasian SK; Aplenc R; Gill S Blood Adv; 2023 Aug; 7(16):4418-4430. PubMed ID: 37171449 [TBL] [Abstract][Full Text] [Related]
13. Engineered Cytokine Signaling to Improve CAR T Cell Effector Function. Bell M; Gottschalk S Front Immunol; 2021; 12():684642. PubMed ID: 34177932 [TBL] [Abstract][Full Text] [Related]
14. Engineering next-generation chimeric antigen receptor-T cells: recent breakthroughs and remaining challenges in design and screening of novel chimeric antigen receptor variants. Mei A; Letscher KP; Reddy S Curr Opin Biotechnol; 2024 Dec; 90():103223. PubMed ID: 39504625 [TBL] [Abstract][Full Text] [Related]
15. Preclinical delayed toxicity studies of BCMA CAR T-cell injection in B-NDG mice with multiple myeloma. Guo J; Wu Q; Li H; Liang C; Dai J; Zhang S; Dai C; Zhang J; Wen Y; Yang W Front Immunol; 2024; 15():1435934. PubMed ID: 39606226 [TBL] [Abstract][Full Text] [Related]
16. Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress. Huang H; Yu L; Weng H; Zhang W; Wang Z; Wang L; Huang H J Hematol Oncol; 2024 Dec; 17(1):120. PubMed ID: 39639359 [TBL] [Abstract][Full Text] [Related]
17. Engraftment of a surrogate antigen onto tumor cell surface via pHLIP peptide to universally target CAR-T cell therapy to solid tumors. Zhang YT; Fu X; Ting Lim JJ; Zhang SX Cancer Lett; 2025 Jan; 608():217319. PubMed ID: 39489212 [TBL] [Abstract][Full Text] [Related]
18. Harnessing the potential of CAR-T cell in lupus treatment: From theory to practice. Alsuliman T; Marjanovic Z; Rimar D; Tarte K; Avcin T; Hagen M; Schett G; Farge D Autoimmun Rev; 2024 Dec; 23(12):103687. PubMed ID: 39532175 [TBL] [Abstract][Full Text] [Related]
19. Case report: CD7-targeted autologous CAR-T therapy for the treatment of T-cell acute lymphoblastic leukemia undergoing allogeneic peripheral blood stem cell transplantation in the long-term follow-up. Li LL; Xia YP; Li Q; Wang P; Sun PP; Wang XG; Zhang R Front Immunol; 2024; 15():1469251. PubMed ID: 39620223 [TBL] [Abstract][Full Text] [Related]
20. Point of care CD19 chimeric antigen receptor (CAR) T-cells for relapsed/refractory acute myeloid leukemia (AML) with aberrant CD19 antigen expression. Danylesko I; Shem-Tov N; Yerushalmi R; Jacoby E; Toren A; Shouval R; Itzhaki O; Avigdor A; Shimoni A; Nagler A Curr Res Transl Med; 2024 Dec; 72(4):103471. PubMed ID: 39305562 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]